Clinicians need education regarding which patients with leukemia are candidates for genetic counseling and testing and how the management of patients with known germline mutations is affected. This knowledge will help clinicians provide these patients with optimal care.

Newer agents used in the treatment of acute lymphoblastic leukemia (ALL) have led to improved clinical outcomes, but are associated with significant toxicities. Clinicians need to be educated on appropriate management approaches for the side effects associated with these new therapies to allow patients to receive maximal benefit and optimal care.

It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.

It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.

The information presented in this talk will address the long-term effects of CAR T-cell therapy, including HLH/MAS, B-cell aplasia, and prolonged cytopenias. Nurses will learn how to recognize signs/symptoms of these effects and how to manage them in order to educate patients and provide ideal care to patients undergoing CAR T-cell therapy.

It is important for health care professionals caring for pediatric patients with ALL to recognize aspects of optimal dosing and frequency, appropriate use in particular genomic alterations, mechanisms of resistance, and patient-specific counseling points to ensure efficacy and compliance of TKIs.

CAR T-cell therapy represents a novel class of immunotherapy and its use has been expanding in relapsed or refractory hematologic malignancies. To ensure optimal patient outcomes, treatment-related toxicities must be closely monitored and quickly managed.

The NCCN Guidelines for pediatric ALL will help inform clinicians about treatment approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.

The NCCN Guidelines for pediatric ALL will help inform clinicians about treatment approaches and will shed light on new prognostic markers that could be targeted in pediatric ALL to enhance therapeutic efficacy and minimize treatment-related toxicities.

With increased use of immunotherapies in ALL treatment, it is important for oncology care providers to be aware of the best ways to incorporate these therapies into standard practice. Additionally, continued education will allow oncology care providers to become very conversant with the unique side effects associated with immunotherapy, leading to the development of appropriate disease management strategies.